Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Integragen had a gross margin of N/A% for the quarter that ended in Jun. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Integragen Gross Margin % Related Terms
Integragen Gross Margin % Historical Data
* Premium members only.
The historical data trend for Integragen's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALINT vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Integragen's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integragen Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Integragen's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Integragen's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Integragen (XPAR:ALINT) has a Gross Margin % of 0.00% as of Jun. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Integragen and its competitors. Over the past decade, Integragen's Gross Margin % has ranged from 9.78 to 95.52. According to the industry distribution chart, Integragen ranks #46 out of 737 companies in the Biotechnology industry, placing it in the top 6.2%.
Is Integragen's Gross Margin % too high?
Integragen's current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 9.78 to a high of 95.52. Based on the distribution chart, Integragen ranks #46 out of 737 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Integragen has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integragen's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Integragen ranks #46 out of 737 companies for Gross Margin %. This places Integragen in the top 6% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.92. Historically, Integragen's own Gross Margin % has ranged from 9.78 to 95.52 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Integragen and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integragen's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integragen stock overvalued right now?
Based on GuruFocus' analysis, Integragen (XPAR:ALINT) is currently considered Possible Value Trap. The stock's GF Value™ is €0.42, compared to a current price of €0.19 — trading 55.7% below its estimated fair value. The current Gross Margin % is 0.00%. Integragen's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Integragen (XPAR:ALINT), the current Gross Margin % is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integragen (XPAR:ALINT) Overvalued in 2026?
Based on GuruFocus' analysis, Integragen stock appears to be undervalued.
The current stock price of €0.19 is trading 55.7% below its estimated GF Value™ of €0.42.
GuruFocus considers Integragen to be Possible Value Trap.
Key valuation signals for XPAR:ALINT:
Gross Margin %: 0.00%
GF Value™: €0.42 vs. price of €0.19 (55.7% below fair value)
No single metric tells the full story. See the XPAR:ALINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integragen is engaged in the development of genetic biomarkers. It offers genomic and bioinformatic services, including clinical research, basic and human genetic research, bioinformatics and bioanalysis, agrigenomics, and genomics news, as well as genomic research tools and solutions to microbiologic researchers.
29GF Score
Get the complete analysis for XPAR:ALINT
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALINT has been successfully added to your 
